The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.
NCT ID: NCT01948804
Last Updated: 2014-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF
NCT02201914
Protocols of IVF/ICSI in Poor Responders
NCT04356105
Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients
NCT01206803
Antagonist/Letrozole in Poor Responders
NCT00823004
Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET
NCT01219153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IVF patients
patients that has applied to Yeditepe University Hospital assisted reproduction center
GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)
microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)
Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)
GnRH antagonist protocol (Cetrotide, Serono)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)
microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)
Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)
GnRH antagonist protocol (Cetrotide, Serono)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Anti müllerian hormone \<1.1 ng/ml and/or a previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol).
2. Primary infertile patients
3. BMI≤30 kg/m2 were included this study.
Exclusion Criteria
18 Years
44 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pınar Özcan Cenksoy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pınar Özcan Cenksoy
Medical Doctor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ytu-123
Identifier Type: OTHER
Identifier Source: secondary_id
ytu-123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.